alexa Is fibromuscular dysplasia underdiagnosed? A comparison of the prevalence of FMD seen in CORAL trial participants versus a single institution population of renal donor candidates.


Journal of Antivirals & Antiretrovirals

Author(s): Hendricks NJ, Matsumoto AH, Angle JF, Baheti A, Sabri SS,

Abstract Share this page

Abstract Renal artery fibromuscular dysplasia (FMD) may be underdiagnosed. We evaluated the prevalence of FMD in CORAL (Cardiovascular Outcomes in Renal Atherosclerotic Lesions) renal artery stent trial participants, in which FMD was an exclusion criterion for inclusion. We also evaluated the prevalence of FMD in a relatively healthy population of patients undergoing computed tomographic angiographic (CTA) screening for renal donor evaluation. All renal donor CTAs performed at our institution from January 2003 through November 2011 were retrospectively reviewed for the presence of FMD along with patient sex and age. These results were compared to angiographic core lab (ACL) findings for the CORAL trial. The CORAL ACL database contained 997 patients (mean age 69.3 years; 50\% female). Fifty-eight (5.8\%) CORAL trial patients (mean age 71.8 years; 75.9\% female) demonstrated incidental FMD. The renal donor cohort included 220 patients (mean age 40.5 years; 64.5\% female). Five (2.3\%) demonstrated FMD (mean age 48.6 years; all female). The odds of FMD in the CORAL cohort were 2.65 times that seen in the renal donor cohort (95\% CI: 1.12, 7.57). In C: onclusion, the 5.8\% prevalence of renal artery FMD in the CORAL trial population, the presence of which was biased against, suggests underdiagnosis. © The Author(s) 2014. This article was published in Vasc Med and referenced in Journal of Antivirals & Antiretrovirals

Relevant Expert PPTs

  • Limin Chen
    An 18- Gene Signature Predicting Treatment Response to Interferon in Patients Chronically Infected with Hepatitis C Virus
    PPT Version | PDF Version
  • Sudha Srivastava
    Novel Inhibitor by Modifying Oseltamivir Based on Neuraminidase Structure for Treating Drug-Resistant H5N1 Virus Using Molecular Docking NMR and DSC Methods
    PPT Version | PDF Version

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version